Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Revenue	$ 0	$ 0
Operating expenses:
General and administrative (including stock- based compensation (Note 7))	1,071,694	1,025,628	3,420,754	4,788,055
Research and development (including stock- based compensation (Note 7))	37,713	28,360	86,319	98,494
Total operating expenses	1,109,407	1,053,988	3,507,073	4,886,549
Loss from operations	(1,109,407)	(1,053,988)	(3,507,073)	(4,886,549)
Other expense (income):
Interest expense	72,068	7,215	127,384	14,430
Interest income	(46)	(695)	(96)	(1,702)
	72,022	6,520	127,288	12,728
Net loss	(1,181,429)	(1,060,508)	(3,634,361)	(4,899,277)
Net loss attributable to the noncontrolling interest	1,393	1,171	2,791	14,274
Net loss attributable to Bion	(1,180,036)	(1,059,337)	(3,631,570)	(4,885,003)
Conversion inducement		(206,678)		(755,258)
Dividends on preferred stock	(1,250)	(1,875)	(2,917)	(151,425)
Net loss applicable to Bion's common Stockholders	$ (1,181,286)	$ (1,267,890)	$ (3,634,487)	$ (5,791,686)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in Dollars per share)	$ (0.07)	$ (0.08)	$ (0.21)	$ (0.40)
Weighted-average number of common shares outstanding:
Basic and diluted (in Shares)	17,196,001	15,818,467	17,061,635	14,634,645